Market Alert : Global Markets Show Mixed Signals Amid Falling Oil Prices, Rising Bond Yields and Persistent US Inflation

Mayank Bansal
Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.

AVITA Medical Reports Cohealyx Study Results: Faster Graft Readiness and Six-Month Healing

AVITA Medical Reports Cohealyx Study Results: Faster Graft Readiness and Six-Month Healing Source: Kapitales Research

Highlights:

  • The Cohealyx I study met its primary endpoint, with median graft readiness of 11 days.
  • About 72% of wounds were ready for skin grafting within two weeks.
  • No Cohealyx-related adverse events were reported through 26 weeks after grafting.

Study Results Released

AVITA Medical (ASX: AVH) announced on 16 November 2026 the complete results of its Cohealyx I study in patients with full-thickness wounds, including six-month follow-up. The data were presented at the Northeastern Regional American Burn Association conference in Boston. Cohealyx is a collagen-based dermal matrix that helps prepare the wound bed for skin grafting. Chief executive Cary Vance said the full results give surgeons a fuller picture of how patients progress after grafting. AVITA shares last traded at AU$4.700, up 4.444%.

Faster Graft Readiness

Mean time to graft readiness was 13.6 days, compared with a 28-day performance goal drawn from published studies of other dermal matrices, a result the company describes as statistically significant. The median was 11 days. The goal was based on research reporting an average time to grafting of 33.2 days. The company says the findings build on evidence reported in April of faster wound bed preparation and high surgeon satisfaction.

Healing and Safety Findings

Tissue samples taken before grafting showed cells entering the matrix, new blood vessel formation and new collagen. Eight weeks after grafting, 88% of patients assessed had healed, and one patient, or 2.5%, needed regrafting. Average Vancouver Scar Scale scores improved from 5.2 at week 12 to 3.5 at week 26, where lower scores mean less scar abnormality.

Who Took Part

The study followed 40 patients, 57.5% with burns and the rest with other wounds. Most, 77.5%, had at least one risk factor for impaired healing, and 65% had severe systemic disease. It was a single-arm study funded by AVITA, and one clinician quoted is a company medical advisor. Follow-up ran to 26 weeks after grafting, although the number of patients assessed varied by visit and endpoint.

Note: All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au